PATENT CLAIM ANALYSIS

Application Number: 15749922
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "210210"]

Abstract:
4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Claim (Index 74):
The compound of  claim 72 , wherein one R 10  is halide and one R 10  is \u2014CH 2 NHSO 2 R 19 .

Metadata:
- Claim Count in Document: 5.0
- Percentile: 88.0
- Lexical Diversity: 1.62319
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15749923', '15749910', '15749929', '15749739', '15749742']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8391158877641759
- 35 USC 102 Novelty (BERT): 0.6176987178353601
- Combined Prediction Score: 0.8169741707712943
- Mean Citation Score: 590.1957719999998
- Max Citation Score: 622.4896
- Similarity Product: 491.6726292541504

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test